ALLMedicine™ Follicular Lymphoma Center

Mar 18th, 2023 - Low-grade follicular lymphoma with extensive marginal zone differentiation and expression of MUM1 and CD30.|2023|Baykara Y,Kurt H,|

Mar 11th, 2023 - Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/immune cells. Follicular lymphoma, mediastinal grey zone lymphoma and diffuse large B-cell lymphomas, may show a TME containing inflammatory/...

Mar 10th, 2023 - Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will...

Mar 10th, 2023 - The study is divided into a phase I dose escalation phase and a phase II expansion phase. Patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL) will receive GDA-20...

Mar 10th, 2023 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Nov 30th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|therapeutic use,diagnosis,epidemiology,therapy,diagnosis,therapy,the...

Jun 25th, 2020 - The investigation and management of follicular lymphoma.|2020|McNamara C,Montoto S,Eyre TA,Ardeshna K,Burton C,|diagnosis,therapy,

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

Jun 14th, 2014 - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for app...

Mar 10th, 2023 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

Mar 10th, 2023 - The study is divided into a phase I dose escalation phase and a phase II expansion phase. Patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL) will receive GDA-20...

Mar 10th, 2023 - Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will...

Mar 9th, 2023 - MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, ...

Mar 9th, 2023 - This is an open-label, multicenter, randomized phase III trial. The study plans to randomize patients with a 1:1 ratio to Arm A (Standard arm) or Arm B (Experimental arm). Once randomized, each patient will start immunochemotherapy with one of the...

Feb 25th, 2023 - Key clinical point: Autologous stem cell transplantation (ASCT) leads to high durable remission rates in patients with relapsed follicular lymphoma (FL), with the functional cure rate elucidated by long-term follow-up being >50%. Major finding: At.

Jan 14th, 2023 - Highlights in follicular lymphoma from the 2022 American Society of Hematology (ASH) Annual Meeting are discussed by Dr Thomas Rodgers of the Durham VA Medical Center. Dr Rodgers begins with a prognostic model designed to evaluate the risk for dis.

Jan 2nd, 2023 - Last year, MedPage Today reported on developments leading to PI3K inhibitors losing multiple indications over safety and efficacy concerns. In this report, we outline what to expect in the coming year. The PI3K inhibitor drug class had a rough go ...

Dec 27th, 2022 - The FDA granted accelerated approval to the bispecific monoclonal antibody mosunetuzumab (Lunsumio) for relapsed/refractory follicular lymphoma after two or more prior lines of therapy. A first-in-class cancer immunotherapy, the drug works by indu...

Dec 5th, 2022 - The Diagnosis: Mid-Borderline Multibacillary Leprosy The biopsies showed a granulomatous dermatitis involving the dermis and subcutaneous adipose tissue (Figure, A). Fite staining also revealed numerous acid-fast bacilli (AFB) throughout the dermi.